Novartis Gets EU Approval for Tabrecta Lung-Cancer Treatment
22 Junho 2022 - 3:05AM
Dow Jones News
By Ed Frankl
Novartis AG said Wednesday that European regulators approved its
lung-cancer treatment Tabrecta.
The Swiss pharmaceutical company said the European Commission
approved Tabrecta, also known as capmatinib, as a single-drug
treatment of adults with certain advanced nonsmall cell lung
cancers.
The approval, based on a Phase 2 trial, follows a positive
opinion issued in April by the European Medicines Agency, Novartis
said.
The approval is applicable to all 27 European Union member
states plus Iceland, Norway and Liechtenstein, the Basel,
Switzerland-based company said.
Write to Ed Frankl at edward.frankl@dowjones.com
(END) Dow Jones Newswires
June 22, 2022 01:50 ET (05:50 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
